196 related articles for article (PubMed ID: 488757)
1. Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease.
Homeida M; Roberts CJ; Halliwell M; Read AE; Branch RA
Gut; 1979 Jul; 20(7):596-601. PubMed ID: 488757
[TBL] [Abstract][Full Text] [Related]
2. Saliva and plasma clearance of antipyrine as reflectors of liver function.
Luoma PV; Sotaniemi EA
Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326
[TBL] [Abstract][Full Text] [Related]
3. The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man.
Roberts CJ; Jackson L; Halliwell M; Branch RA
Br J Clin Pharmacol; 1976 Oct; 3(5):907-13. PubMed ID: 973986
[TBL] [Abstract][Full Text] [Related]
4. Fractional clearance of bromosulfonephthalein and metabolic clearance of antipyrine. Correlative study in liver diseases.
Couet C; Brissot P; Messner M; Delamaire D; Gie S; Bourel M
Ann Gastroenterol Hepatol (Paris); 1984; 20(1):1-6. PubMed ID: 6529154
[TBL] [Abstract][Full Text] [Related]
5. The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease.
Branch RA; James JA; Read AE
Clin Pharmacol Ther; 1976 Jul; 20(1):81-9. PubMed ID: 1277728
[TBL] [Abstract][Full Text] [Related]
6. Disposition of antipyrine and phenytoin correlated with age and liver volume in man.
Bach B; Hansen JM; Kampmann JP; Rasmussen SN; Skovsted L
Clin Pharmacokinet; 1981; 6(5):389-96. PubMed ID: 7333060
[TBL] [Abstract][Full Text] [Related]
7. Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan.
Figg WD; Dukes GE; Lesesne HR; Carson SW; Songer SS; Pritchard JF; Hermann DJ; Powell JR; Hak LJ
Pharmacotherapy; 1995; 15(6):693-700. PubMed ID: 8602375
[TBL] [Abstract][Full Text] [Related]
8. Antipyrine metabolism during hepatic regeneration in the rat.
Poulsen HE; Pilsgaard H
Liver; 1985 Aug; 5(4):196-9. PubMed ID: 4058271
[TBL] [Abstract][Full Text] [Related]
9. Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases.
Kawasaki S; Sugiyama Y; Iga T; Hanano M; Beppu T; Sugiura M; Sanjo K; Idezuki Y
Clin Pharmacol Ther; 1988 Aug; 44(2):217-24. PubMed ID: 3396264
[TBL] [Abstract][Full Text] [Related]
10. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.
Teunissen MW; Spoelstra P; Koch CW; Weeda B; van Duyn W; Janssens AR; Breimer DD
Br J Clin Pharmacol; 1984 Nov; 18(5):707-15. PubMed ID: 6508980
[TBL] [Abstract][Full Text] [Related]
11. Antipyrine disposition and liver size in the elderly.
Swift CG; Homeida M; Halliwell M; Roberts CJ
Eur J Clin Pharmacol; 1978 Nov; 14(2):149-52. PubMed ID: 720377
[TBL] [Abstract][Full Text] [Related]
12. Effect of acute and chronic propranolol administration on antipyrine and paracetamol clearance in patients with chronic liver disease.
Hayes PC; Bouchier IA
Am J Gastroenterol; 1989 Jul; 84(7):723-6. PubMed ID: 2741882
[TBL] [Abstract][Full Text] [Related]
13. The use of antipyrine clearance to measure liver damage in psoriatic patients receiving methotrexate.
Paramsothy J; Strange R; Sharif H; Collins M; Shaw P; Lawrence CM
Br J Dermatol; 1988 Dec; 119(6):761-5. PubMed ID: 3203069
[TBL] [Abstract][Full Text] [Related]
14. Clearance of antipyrine-dependence of quantitative liver function.
Andreasen PB; Ranek L; Statland BE; Tygstrup N
Eur J Clin Invest; 1974 Apr; 4(2):129-34. PubMed ID: 4832718
[No Abstract] [Full Text] [Related]
15. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
[TBL] [Abstract][Full Text] [Related]
16. Impairment of drug elimination in patients with liver disease.
Narang AP; Datta DV; Mathur VS
Int J Clin Pharmacol Ther Toxicol; 1985 Jan; 23(1):28-32. PubMed ID: 3988389
[TBL] [Abstract][Full Text] [Related]
17. Antipyrine clearance and metabolite formation in primary biliary cirrhosis.
Jorquera F; Almar M; Linares A; Olcóz JL; Rodrigo L; González-Gallego J
Dig Dis Sci; 2001 Feb; 46(2):352-9. PubMed ID: 11281185
[TBL] [Abstract][Full Text] [Related]
18. [Comparative study on the elimination of pindolol (visken) and antipyrin in patients with liver diseases].
Ohnhaus EE; Münch U; Meier J
Schweiz Med Wochenschr; 1976 Dec; 106(49):1748-50. PubMed ID: 1013699
[TBL] [Abstract][Full Text] [Related]
19. Salivary antipyrine kinetics in hepatic and renal disease and in patients on anticonvulsant therapy.
Harman AW; Penhall RK; Priestly BG; Frewin DB; Phillips PJ; Clarkson AR
Aust N Z J Med; 1977 Aug; 7(4):385-90. PubMed ID: 270989
[TBL] [Abstract][Full Text] [Related]
20. Liver volume, portal vein flow, and clearance of indocyanine green and antipyrine in hyperthyroidism before and after antithyroid treatment.
Andersen V; Sonne J; Court-Payen M; Sletting S; Prip A; Mølholm Hansen J
Scand J Gastroenterol; 1999 Jun; 34(6):618-22. PubMed ID: 10440613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
